The NIH just got an IND — Investigational New Drug application — cleared by the FDA for mitragynine, the primary psychoactive compound in kratom, to be tested as a treatment for opioid use disorder in a Phase I clinical trial. That's a concrete step for a compound that millions have already been self-experimenting with, but that has never been rigorously studied in isolation in humans.
Mitragynine is the main alkaloid in Mitragyna speciosa (kratom), a tropical tree native to Southeast Asia. People have long used kratom tea for opioid withdrawal and pain management, but raw kratom contains dozens of active compounds that interact unpredictably with opioid receptors. Preclinical work from the University of Florida and NIH’s National Center for Advancing Translational Sciences (NCATS) and NIDA showed that the therapeutic effects likely come from the slow metabolic conversion of mitragynine in the body, not from direct receptor binding.
Why Purified Mitragynine Instead of Raw Kratom
Raw kratom is a mess — variable potency, multiple alkaloids, and no quality control. The researchers developed a purified formulation of mitragynine, and animal studies across several doses found no significant safety red flags. The IND clearance means the FDA agrees the preclinical data are sufficient to move into humans. This is the first time a purified kratom isolate will be studied in a controlled clinical setting.
What the Phase I Trial Actually Looks Like
NIDA Director Nora Volkow put it bluntly: “This IND is a major step toward expanding treatment options for the millions of Americans struggling with opioid use disorder, which has contributed to historically high overdose mortality rates.” The trial is randomized, double-blind, and placebo-controlled — the gold standard for eliminating bias. The primary endpoint is safety and tolerability. If the compound passes Phase I, it opens the door to efficacy studies that could actually demonstrate whether mitragynine helps people maintain recovery and reduce cravings.
NCATS Director Joni Rutter noted that they’ve “seen the potential of mitragynine in the lab, and now we’re finally able to examine its potential in people.” The trial is funded under the NIH HEAL Initiative, a cross-agency push to accelerate solutions for the opioid crisis.
What This Changes
Right now, approved medications for opioid use disorder — methadone, buprenorphine, naltrexone — work well but aren't perfect. Many patients struggle with access, side effects, or simply don't respond. Mitragynine could offer a different pharmacological profile, potentially with less respiratory depression or abuse liability, though that remains to be proven. A successful Phase I would put a new chemical entity on the treatment map that came not from a pharma lab but from a plant that people have been using for centuries. The NIH is betting that rigorous science can turn that folk knowledge into a real drug.
Source: NIH research clears way for study of experimental treatment for opioid use disorder
Domain: nih.gov
Comments load interactively on the live page.